Jie He

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database

Gaurav Singal, Peter G. Miller, Vineeta Agarwala et al. · JAMA · 2019 · 565 citations · Full text

Medicine, Biomedical Informatics, Oncology +16

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma

Allen S. Ho, Angelica Ochoa, Gowtham Jayakumaran et al. · Journal of Clinical Investigation · 2019 · 210 citations · Full text

Medicine, Genetics, Oncology +10

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib

Sai‐Hong Ignatius Ou, Michele C. Azada, David Hsiang et al. · Journal of Thoracic Oncology · 2014 · 169 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

Susan Dent, Javier Cortés, Young‐Hyuck Im et al. · Annals of Oncology · 2020 · 163 citations · Full text

Medicine, Oncology, Pharmacology +15

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

Siraj M. Ali, Thomas A. Hensing, Alexa B. Schrock et al. · The Oncologist · 2016 · 115 citations · Full text

Medicine, Genetics, Oncology +17